Chinese inhibitor drug candidate becomes first to enter phase
Time:2024-06-03 13:16:50 Source:styleViews(143)
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Previous:Chris Hemsworth's $168m Mad Max film Furiosa flops in Australia making only $3m opening weekend
Next:Reliever Drew Smith back with Mets after missing almost 6 weeks with shoulder soreness
You may also like
- Maldives will ban Israelis from entering the country over the war in Gaza
- Biden will deliver Morehouse commencement address during a time of tumult on US college campuses
- Leverkusen go 49 matches unbeaten to set new record
- Ant sets the record straight: TV star breaks his silence on THAT tattoo
- Paris Olympics: What to know and who to watch during the breakdancing competition
- Chinese paddlers continue winning streak at WTT Champions Incheon
- Arango, Gómez each score 2 goals, RSL rallies for 5
- Jeff Daniels feared THAT toilet scene in 1994's Dumb And Dumber would 'end' his acting career
- Real Madrid vs Borussia Dortmund